187834-88-4

Basic information

• Product Name: 1-BOC-ISONIPECOTIC ACID HYDRAZIDE
• Synonyms: TERT-BUTYL 4-(HYDRAZINOCARBONYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;1-BOC-ISONIPECOTIC ACID HYDRAZIDE;1-Boc-piperidine-4-carboxylhydrazide;N-Boc-piperidine-4-carboxylhydrazide;1-(tert-Butoxycarbonyl)piperidine-4-carbohydrazide;Isonipecotic acid hydrazide, N1-BOC protected, 4-(Hydrazinocarbonyl)piperidine, N1-BOC protected, tert-Butyl 4-(hydrazinocarbonyl)piperidine-1-carboxylate;1-Boc-4-(hydrazinocarbonyl)piperidine;4-(hydrazinecarbonyl)-1-piperidinecarboxylic acid tert-butyl ester
• CAS NO: 187834-88-4
• Molecular Formula: C₁₁H₂₁N₃O₃
• Molecular Weight: 243.3
• Mol File: 187834-88-4.mol
• Article Data: 23

Chemical Properties

• Melting Point: 104-106°C
• Boiling Point: 409.223 °C at 760 mmHg
• Flash Point: 201.291 °C
• Appearance: /
• Density: 1.148 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.508
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 13.01±0.20(Predicted)
• CAS DataBase Reference: 1-BOC-ISONIPECOTIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-ISONIPECOTIC ACID HYDRAZIDE(187834-88-4)
• EPA Substance Registry System: 1-BOC-ISONIPECOTIC ACID HYDRAZIDE(187834-88-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 187834-88-4(Hazardous Substances Data)

Usage

General Description

1-BOC-ISONIPECOTIC ACID HYDRAZIDE is a chemical compound predominantly used in various fields of scientific research. It has multiple applications due to its interesting chemical properties, including being frequently used as a reagent in the synthesis of other complex compounds in pharmaceutical research. Due to its active hydrazide group, it can also engage in several reactions, including condensation, coupling and reduction. As with all chemicals, it requires careful handling and storage under suitable conditions to maintain its stability and integrity. The exact properties of this chemical, including potential hazards or reactions, would be determined by full scientific testing and analysis.

InChI:InChI=1/C11H21N3O3/c1-11(2,3)17-10(16)14-6-4-8(5-7-14)9(15)13-12/h8H,4-7,12H2,1-3H3,(H,13,15)

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 1126-09-6 4-carbethoxypiperidine 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2971-79-1 isonipecotic acid methyl ester 
• 64269-79-0 Carbonyldiimidazole 
• 293744-38-4 tert-butyl 4-(1H-imindazole-1-carbonyl)piperidine-1-carboxylate 

Downstream Products

• 280110-70-5 4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1245832-99-8 C₁₈H₂₅N₅O₂ 
• 1312793-98-8 tert-butyl 4-(2-(3-cyclopentyloxy-4-methoxybenzoyl)hydrazinecarbonyl)piperidine-1-carboxylate 
• 1312793-99-9 2-(3-cyclopentyloxy-4-methoxyphenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole 
• 1312794-00-5 tert-butyl 4-(5-(3-(cyclopentyloxy)-4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)piperidine-1-carboxylate 
• 1312794-01-6 2-(3-cyclopentyloxy-4-methoxyphenyl)-5-(piperidin-4-yl)-1,3,4-thiadiazole 
• 297171-80-3 4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidine hydrochloride 
• 42596-58-7 piperidine-4-carboxylic acid hydrazide 
• 917363-98-5 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyrazin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917363-81-6 (3-phenyl-2-{4-[4-(5-pyridin-2-yl-4H-[1,2,4]triazol-3-yl)-piperidin-1-ylmethyl]-phenyl}-[1,6]naphthyridin-5-yl)-hydrazine 
• 917363-81-6 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 
• 917364-00-2 5-hydrazino-3-phenyl-2-(4-{[4-(5-pyrimidin-2-yl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridine 

Relevant articles and documents

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease

A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.

TBSOTf-promoted versatile N-formylation using DMF at room temperature

Hydrazides and amines were N-formylated by DMF in the presence of tert-butyldimethylsilyl triflate (TBSOTf) at room temperature, in good to excellent yields.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.